ISPOR - Evidence for a Lowered Threshold for FDA Approval of Oncologics Based on Single-Arm Phase II Data, Compared to the EMA

Full Text

Evidence for a Lowered Threshold for FDA Approval of Oncologics Based on Single-Arm Phase II Data, Compared to the EMA

Abstract

Authors

R. Macaulay

Back to Volume 17, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now